Physician profile
James M Morrison
NPI 1437352523
$12,544.89
in general payments reported to CMS, 2019-2025
37 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $2,239 · 2021: $2,470 · 2022: $1,640 · 2023: $1,564 · 2024: $1,180 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201 · Education: $77.27 · Entertainment: $13.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.23 |
| Education | $77.27 |
| Entertainment | $13.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,765.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,520.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $995.87 | 2019-2025 | |
| Amgen INC. | $659.21 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $641.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $509.74 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.40 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $445.40 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $413.60 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $350.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $324.63 | 2019-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Janssen Pharmaceuticals, INC | $318.39 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.47 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.88 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $195.90 | 2019-2024 | Veozah, Myrbetriq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $189.33 | 2022-2025 | Heplisav-B |
| Exact Sciences Corporation | $148.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $141.56 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $113.31 | 2019-2020 | |
| Allergan, INC. | $104.37 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $92.13 | 2021 | |
| Daiichi Sankyo INC. | $84.75 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $84.42 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $81.02 | 2019-2025 | |
| Abbott Laboratories | $69.31 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.35 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $48.91 | 2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $41.05 | 2019-2020 | |
| Eisai INC. | $37.95 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.97 | 2020-2022 | |
| Genentech USA, INC. | $27.58 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.69 | 2025 | Inspire |
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $19.84 | 2023 | Sunosi |
| Optos, INC. | $13.77 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Gilead Sciences, INC. | $13.07 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.